Xueda Education Group (XUE)
XUE reported on its financial results, not only robust operating results for the third quarter but for the first time in XUE ’s history, positive net earnings results in the third quarter period..
For the third quarter 2013, XUE posted total net revenues of $79.4 million, a 14.2% increase year over year, gross profit of $23.2 million, increased by 74.3% compared to the same period the prior year, and net income attributable to XUE of $1.2 million, compared to a net loss of $3.6 million in the third quarter of 2012.
Diluted net income attributable to XUE per American Depositary Share (ADS) for the third quarter of 2013 was $0.02, compared to a diluted net loss per ADS of ($0.05) for the third quarter of 2012.
XUE is a leading national provider of personalized tutoring services for primary and secondary school students in China.
More about Xueda Education Group (XUE) at ir.xueda.com .
**
Crown Equity Holdings Inc. (CRWE)
Corporate buyers are comfortable and willing to make major purchase online, and many are already doing this, but not on suppliers’ web sites. With online spend expected to rise in the next year, suppliers who don’t invest in e-commerce and multichannel initiatives will miss out on revenue gains from this channel
U.S. companies and government agencies will purchase $559 billion via the web in 2013, Forrester Research Inc. predicted in its first estimate of the b2b e-commerce market released last year.
CRWE is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar online b2b market with its iB2B Global project..
As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
**
Dynasil Corporation of America (DYSL)
DYSL reported that its contract research subsidiary, RMD Inc., has received four grants totaling $4.0 million under the U.S. Department of Energy's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.
From accounting for the country's nuclear fuel supply to monitoring the 15 million shipping containers that enter the U.S.' ports every year for illicit nuclear materials, the new Phase II research projects DYSL 's RMD is undertaking through these SBIR/STTR Programs exemplify some of the world's most demanding security and safety needs.
DYSL 's RMD work has significant application in the prevention of terrorist attacks and the safe guarding of nuclear materials, as well as in commercial endeavors such as energy exploration, nuclear power plant safety, medical imaging, basic science research and non-destructive testing.
DYSL develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets including medical imaging and sensors for non-destructive testing.
More about Dynasil Corporation of America (DYSL) at www.dynasil.com .
**
ImmunoGen, Inc. (IMGN)
IMGN reported that the European Commission has granted marketing approval for Kadcyla (trastuzumab emtansine; ado-trastuzumab emtansine in the US) in the European Union (EU). This event triggers a $5 million milestone payment to IMGN.
Kadcyla has been approved for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast-cancer who previously received Herceptin(R) (trastuzumab) and a taxane, separately or in combination.
As with the Kadcyla approvals that have been granted in the US, Japan, and other geographies, the approval in the EU is based on the findings in the EMILIA Phase III trial. In the EU and other international markets, the timing of the commercial availability of Kadcyla after approval can vary due to national differences in processes for establishing pricing/reimbursement, with some countries – including Germany – able to launch shortly after approval.
Kadcyla consists of Roche’s trastuzumab antibody with IMGN ’s DM1 cytotoxic agent attached using one of the Company’s engineered linkers. Roche has global development and commercialization rights for Kadcyla; IMGN is entitled to receive royalties on product sales as well as specified milestone payments.
IMGN develops targeted anticancer therapeutics. Its ADC technology uses a tumor-targeting engineered antibody to deliver one of IMGN 's highly potent cancer-cell killing agents specifically to tumor cells.
More about ImmunoGen, Inc. (IMGN) at www.immunogen.com .
**
Read Full Disclaimer at www.drstockpick.com/disclaimer
